Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + filgrastim
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Epirubicin + filgrastim is a combination regimen used primarily in oncology to enable higher-dose or dose-dense chemotherapy by mitigating the risk of severe neutropenia. Epirubicin is an anthracycline antineoplastic agent that intercalates DNA and inhibits topoisomerase II, leading to cytotoxicity in rapidly dividing cancer cells. Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the proliferation and differentiation of neutrophil precursors, reducing the incidence, severity, and duration of chemotherapy-induced neutropenia. This combination allows for intensified or more frequent administration of epirubicin-containing regimens by supporting faster recovery of white blood cell counts[1][2][3][6].
02
Targets
TOP2A (DNA topoisomerase II)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on epirubicin + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + filgrastim.